Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/55904
Type
ArticleCopyright
Restricted access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- INI - Artigos de Periódicos [3650]
Metadata
Show full item record
IMPACT OF PREEXISTING ANTI-ADENOVIRUS 26 HUMORAL IMMUNITY ON IMMUNOGENICITY OF THE AD26.COV2.S CORONAVIRUS DISEASE 2019 VACCINE
Author
Affilliation
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Research and Development. Beerse, Belgium.
Janssen Research and Development. Beerse, Belgium.
Janssen Research and Development. Beerse, Belgium.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
South African Research Council. Cape Town, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Alabama. Department of Medicine. Birmingham, Alabama, USA.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Research and Development. Beerse, Belgium.
Janssen Research and Development. Beerse, Belgium.
Janssen Research and Development. Beerse, Belgium.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
South African Research Council. Cape Town, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Alabama. Department of Medicine. Birmingham, Alabama, USA.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Janssen Vaccines and Prevention. Leiden, the Netherlands.
Abstract
This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein-binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.
Share